Inclusion Criteria:  Patients aged 18 years and older Patients with severe asthma with an eosinophilic phenotype eligible for first time treatment with FASENRA according to the indication as indicated in the locally approved prescribing information Patients with evidence of a personally signed and dated informed consent document indicating that the patient (or a legally acceptable representative) has been informed of all pertinent aspects of the study.  Exclusion Criteria:  Hypersensitivity to the active substances or to any of the excipients Current participation in any interventional trial